The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Smolonogina T.A.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Isakova-Sivak I.N.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Kotomina T.S.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Evsina A.S.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Stepanova E.A.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Prokopenko P.I.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Leontieva G.F.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Suvorov A.N.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Rudenko L.G.

Federal State Budgetary Scientific Institution «Institute of Experimental Medicine», 197376 St. Petersburg, Russia, Akad. Pavlova Street, 12, Russia

Generation of a vector vaccine against group B streptococcal infection on the base of a cold-adapted influenza A virus

Authors:

Smolonogina T.A., Isakova-Sivak I.N., Kotomina T.S., Evsina A.S., Stepanova E.A., Prokopenko P.I., Leontieva G.F., Suvorov A.N., Rudenko L.G.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2019;37(1): 25‑34

DOI: 10.17116/molgen20193701125

Views: 4120

Downloaded: 111

Download PDF (RU)
Contact the author
Table of contents

GENERATION OF A VECTOR VACCINE AGAINST GROUP B STREPTOCOCCAL INFECTION ON THE BASE OF A COLD-ADAPTED INFLUENZA A VIRUS
GENERATION OF A VECTOR VACCINE AGAINST GROUP B STREPTOCOCCAL INFECTION ON THE BASE OF A COLD-ADAPTED INFLUENZA A VIRUS

To cite this article:

Smolonogina TA, Isakova-Sivak IN, Kotomina TS, et al. . Generation of a vector vaccine against group B streptococcal infection on the base of a cold-adapted influenza A virus. Molecular Genetics, Microbiology and Virology. 2019;37(1):25‑34. (In Russ.)
https://doi.org/10.17116/molgen20193701125

Подписка 2025-2 (Molecular Genetics, Microbiology and Virology)
 
МСФ на ЯМ
Close metadata

The aim of the study was the development of a cold-adapted influenza A (H7N9) strain-based vector vaccine expressing epitopes of conservative lipoprotein of Streptococcus agalactiae. Recombinant hemagglutinin (HA) genes of live attenuated influenza vaccine (LAIV) strain A/Anhui/1/2013(H7N9) with insertions of group B Streptococcus (GBS) surface antigen ScaAB gene parts of different length in-frame between signal peptide and HA1 were constructed by the means of reverse genetics. Viral vector vaccine H7-ScaAB-85 expressing the smallest (85 amino acids) polypeptide from lipoprotein ScaAB linked to HA via flexible linker was genetically stable, replicated in embryonated chicken eggs and MDCK cells at the same level as cold-adapted influenza A(H7N9) strain. Increase of ScaAB polypeptide insertion length up to 141 amino acids resulted in decrease of viral replication level in both susceptible systems and intensive mutagenesis of hybrid HA-gene of recombinant influenza A virus in gene region coding foreign bacterial lipoprotein. These findings suggest that H7-ScaAB-85 is a promising vaccine candidate, which should be further assessed using mouse model.

Keywords:

vector vaccines
attenuated influenza virus
Streptococcus agalactiae
genetic engineering
lipoprotein ScaAB

Authors:

Smolonogina T.A.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Isakova-Sivak I.N.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Kotomina T.S.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Evsina A.S.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Stepanova E.A.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Prokopenko P.I.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Leontieva G.F.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Suvorov A.N.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Rudenko L.G.

Federal State Budgetary Scientific Institution «Institute of Experimental Medicine», 197376 St. Petersburg, Russia, Akad. Pavlova Street, 12, Russia

List of references:

  1. De Amicis KM, Freschi de Barros S, Alencar RE, Postól E, Martins Cde O, Arcuri HA, et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes. Vaccine. 2014;32(32):4104-4110.
  2. Edwards MS, Baker CJ. Group B Streptococcal infections in elderly adults. Clin Infect Dis. 2005;41:839-847.
  3. Farley MM. Group B Streptococcal disease in nonpregnant adults. Clin Infect Dis. 2001;33:556-561.
  4. Berardi A, Cattelani C, Creti R, Berner R, Pietrangiolillo Z, Margarit I, et al. Group B Streptococcal infections in the newborn infant and the potential value of maternal vaccination. Expert Rev Anti Infect Ther. 2015;13(11):1387-1399.
  5. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012;379(9815):547-556.
  6. Simoes JA, Aroutcheva AA, Heimler I, Faro S. Antibiotic resistance patterns of Group B Streptococcal clinical isolates. Infect Dis Obstet Gynecol. 2004;12:1-8.
  7. Heelan JS, Hasenbein ME, McAdam AJ. Resistance of Group B Streptococcus to selected antibiotics, including erythromycin and clindamycin. J Clin Microbiol. 2004;42:1263-1264.
  8. Mousavi SM, Nasaj M, Hosseini SM, Arabestani MR. Survey of strain distribution and antibiotic resistance pattern of group B streptococci (Streptococcus agalactiae) isolated from clinical specimens. GMS Hyg Infect Control. 2016;11:Doc18. https://doi.org/10.3205/dgkh000278
  9. Heath PT. Status of vaccine research and development of vaccines for GBS. Vaccine. 2016;34(26):2876-2879.
  10. Cieslewicz MJ, Chaffin D, Glusman G, Kasper D, Madan A, Rodrigues S, et al. Structural and Genetic Diversity of Group B Streptococcus Capsular Polysaccharides. Infect Immun. 2005;73(5):3096-3103.
  11. Garcia-Sastre A, Palese P. Influenza virus vectors. Biologicals. 1995;23(2):171-178.
  12. De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, Bogaert P, et al. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J Virol. 2013;87(6):3314-3323.
  13. Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y, et al. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice. Antiviral Res. 2014;104:110-117.
  14. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther. 1999;10(9):1533-1544.
  15. Lee YN, Hwang HS, Kim MC, Lee YT, Lee JS, Moore ML, et al. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease. Antiviral Res. 2015;115:1-8.
  16. Rudenko LG, Lonskaya NI, Klimov AI, Vasilieva RI, Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3—14-year-olds. Bull World Health Organ. 1996;74(1):77-84.
  17. Rudenko LG, Arden NH, Grigorieva E, Naychin A, Rekstin A, Klimov AI, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine. 2000;19(2-3):308-318.
  18. Doroshenko EM, Grigor’eva EP. Safety, Immunogenicity and Efficacy of Live Attenuated Intranasal Influenza Vaccine — the Experience of Many Years of Use in Different Age Groups. Epidemiology & Vaccinal Prevention. 2013;4(71):67-73. (In Russ.)
  19. Isakova-Sivak I, Tretiak T., Rudenko L. Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. Expert Rev Vaccines. 2016;15(10):1241-1243.
  20. Vorobieva EI, Meringova LF, Leontieva GF, Grabovskaya KB, Suvorov AN. Analysis of recombinant group B streptococcal protein ScaAB and evaluation of its immunogenicity. Folia Microbiol (Praha). 2005;50(2):172-176.
  21. Isakova-Sivak I, Chen LM, Matsuoka Y, Voeten JT, Kiseleva I, Heldens JG, et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology. 2011;412(2):297-305.
  22. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene. 1938;27(3):493-497.
  23. McMillan DJ, Batzloff MR, Browning CL, Davies MR, Good MF, Sriprakash KS, et al. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine. 2004;22(21-22):2783-2790.
  24. Lee YN, Hwang HS, Kim MC, Lee YT, Cho MK, Kwon YM, et al. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology. 2015;476:217-225.
  25. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research. 2014;42(W1):252-258.
  26. Souza AP, Haut L, Reyes-Sandoval A, Pinto AR. Recombinant viruses as vaccines against viral diseases. Braz J Med Biol Res. 2005;38(4):509-522.
  27. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2(3):624-641.
  28. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477.
  29. Berns KI, Byrne BJ, Flotte TR, Gao G, Hauswirth WW, Herzog RW, et al. Adeno-associated virus type 2 and hepatocellular carcinoma? Human gene therapy. 2015;26(12):779-781.
  30. Russell DW, Grompe M. Adeno-associated virus finds its disease. Nature genetics. 2015;47(10):1104.
  31. Saxena M, Van TT, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity against vaccine vectors — friend or foe? Microbiology. 2013;159:1-11.
  32. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? Journal of Experimental Medicine. 2008;205(1):7-12.
  33. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine. 2009;361(23):2209-2220.
  34. Breen M, Nogales A, Baker SF, Martínez-Sobrido L. Replication-competent Influenza A viruses expressing reporter genes. Viruses. 2016;8(7):179.
  35. Suvorov AN, Grabovskaia KB, Leont’eva GF, Meringova LF, Koroleva IN, Duplik NV i dr. Recombinant fragments of conservative proteins of group B Streptococci as a basis of specific vaccine. Zh Mikrobiol Epidemiol Immunobiol. 2010;2:44-50. (In Russ.)
  36. Jenkinson HF. Cell surface protein receptors in oral streptococci. FEMS Microbiol Lett. 1994;121(2):133-140.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.